Reduction of gastrointestinal tract colonisation by campylobacter

Abstract

Campylobacter are the commonest reported bacterial causes of gastroenteritis in the UK and industrialized worlds. This invention relates to a method of preventing or reducing the colonisation of the gastrointestinal tract of an animal with Campylobacter. Accordingly, the present invention provides a method for disinfection of an animal comprising administering to said animal at least one compound that binds to MOMP or FlaA of Campylobacter in an effective amount to reduce the number of Campylobacter present in the gastrointestinal tract of said animal. The present invention also provides a method of preventing or reducing transmission of Campylobacter from one animal to another.

1 - 29 . (canceled) 
     
     
         30 . A composition comprising ferric quinate, complex of a 3,4-dihydroxyphenylalanine or tyrosine with Fe III or a compound with a structure selected from the group consisting of: 
       
         
           
           
               
               
           
         
         in an effective amount to reduce the number of  Campylobacter  present in the gastrointestinal tract of a human subject. 
       
     
     
         31 . The composition of  claim 30 , wherein the composition is a food supplement, drinking water or drinking water supplement. 
     
     
         32 . The composition of  claim 30 , wherein the compound is present in a concentration range between 34 to 340 μM. 
     
     
         33 . The composition of  claim 30 , wherein the compound specifically binds to at least one amino acid residue selected from the group consisting of Arg 3S2 , Thr 268 , Lys 278 , Lys 385 , Asn 258 , Leu 290 , Tyr 294 , Phe 395 , Ile 337 , Arg 381 , Asp 261 , and Ser 397  of MOMP (SEQ ID NO:1). 
     
     
         34 . The composition of  claim 33 , wherein the compound specifically binds to at least amino acid residue Thr 268  of MOMP (SEQ ID NO.1). 
     
     
         35 . The composition of  claim 30 , wherein the compound reduces the campylobacter colony forming units in the gastrointestinal tract of the animal by at least 50%. 
     
     
         36 . The composition of  claim 30 , the  Campylobacter  is  Campylobacter jejuni  or  Campylobacter coli.    
     
     
         37 . The composition of  claim 30 , wherein the compound is a complex of Fe III with 3,4-dihydroxyphenylalanine or tyrosine. 
     
     
         38 . The composition of  claim 30 , wherein the compound is ferric quinate. 
     
     
         39 . A method for treating or reducing  Campylobacter  colonization in a human subject comprising administering to the human the composition of claim  1 . 
     
     
         40 . The method of  claim 39 , wherein the  Campylobacter  is  Campylobacter jejuni  or  Campylobacter Coli.    
     
     
         41 . The method of  claim 39 , wherein the compound is administered orally. 
     
     
         42 . The method of  claim 39 , wherein the compound specifically binds to at least one amino acid residue selected from the group consisting of Arg 3S2 , Thr 268 , Lys 278 , Lys 385 , Asn 258 , Leu 290 , Tyr 294 , Phe 395 , Ile 337 , Arg 381 , Asp 261 , and Ser 397  of MOMP (SEQ ID NO:1). 
     
     
         43 . The method of  claim 39 , wherein the compound specifically binds to at least amino acid residue Thr 268  of MOMP (SEQ ID NO.1). 
     
     
         44 . The method of  claim 39 , wherein the compound reduces the campylobacter colony forming units in the gastrointestinal tract of the animal by at least 50%. 
     
     
         45 . The method of  claim 39 , wherein the compound is a complex of Fe III with 3,4-dihydroxyphenylalanine or tyrosine. 
     
     
         46 . The method of  claim 39 , wherein the compound is ferric quinate.